118 related articles for article (PubMed ID: 2423797)
1. Antihypertensive therapy with indoramin: risk-benefit profile in clinical practice.
Stannard M; Cohen M; Marrott PK; Pascucci VL
J Cardiovasc Pharmacol; 1986; 8 Suppl 2():S48-52. PubMed ID: 2423797
[TBL] [Abstract][Full Text] [Related]
2. [Open study on the effect and side effects of indoramin, used at the 2d and 3d therapeutic step in essential hypertension].
Hitzenberger G; Korn A
Wien Med Wochenschr; 1985 Sep; 135(17):425-30. PubMed ID: 4060742
[TBL] [Abstract][Full Text] [Related]
3. A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL).
Tytus RH; Burgess ED; Assouline L; Vanjaka A
Clin Ther; 2007 Feb; 29(2):305-15. PubMed ID: 17472822
[TBL] [Abstract][Full Text] [Related]
4. Indoramin in the treatment of hypertension.
Stannard M; Cohen M
Practitioner; 1983 Oct; 227(1384):1601-5. PubMed ID: 6634630
[No Abstract] [Full Text] [Related]
5. Antihypertensive therapy with indoramin in the elderly.
Deitch MW; Allen IE; Pascucci VL
J Cardiovasc Pharmacol; 1986; 8 Suppl 2():S88-92. PubMed ID: 2423807
[TBL] [Abstract][Full Text] [Related]
6. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
8. Indoramin as second step therapy in the management of benign essential hypertension.
Montenero AS; Mazzari M; Schiavoni G; Manzoli U; Gherardi S
Pharmatherapeutica; 1983; 3(6):417-21. PubMed ID: 6353433
[TBL] [Abstract][Full Text] [Related]
9. Antihypertensive therapy in the Federal Republic of Germany: clinical practice experience with indoramin (Wydora).
Grube E; Giesing M
J Cardiovasc Pharmacol; 1986; 8 Suppl 2():S43-7. PubMed ID: 2423796
[TBL] [Abstract][Full Text] [Related]
10. [The safety of long-term administration of losartan in current clinical practice: a non-intervention NCT-CZ 14/04/LOZ study].
Krupicka J; Ceypová K; Kristenová P; Hauser T
Vnitr Lek; 2008 Nov; 54(11):1031-8. PubMed ID: 19069675
[TBL] [Abstract][Full Text] [Related]
11. Felodipine extended release versus conventional diuretic therapy for the treatment of systolic hypertension in elderly patients. The National Trial Group.
McClennen W; Wilson T
Clin Invest Med; 1998 Jun; 21(3):142-50. PubMed ID: 9627768
[TBL] [Abstract][Full Text] [Related]
12. Effects of indoramin therapy on BP, renal function, and body fluid composition.
Bauer JH; Jones LB; Gaddy P
Arch Intern Med; 1984 Feb; 144(2):308-12. PubMed ID: 6696567
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
[TBL] [Abstract][Full Text] [Related]
14. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
[TBL] [Abstract][Full Text] [Related]
15. A double blind comparison of indoramin with clonidine in the treatment of moderate to severe essential hypertension.
Yajnik BH; Shah JS
J Assoc Physicians India; 1985 May; 33(5):339-43. PubMed ID: 3900029
[No Abstract] [Full Text] [Related]
16. Clinic blood pressure responses to two amlodipine salt formulations, adipate and besylate, in adult Korean patients with mild to moderate hypertension: a multicenter, randomized, double-blind, parallel-group, 8-week comparison.
Lee HY; Kang HJ; Koo BK; Oh BH; Heung-Sun K; Kim KS; Seo HS; Ro YM; Kang JH; Woong CJ; Joo SJ; Kim MH; Joon-Han S; Yoon J; Park SH; Jin-Ok J; Ju AK; Chong-Yun R; Yeon KJ; Park KM; Lim DK; Park SY;
Clin Ther; 2005 Jun; 27(6):728-39. PubMed ID: 16117979
[TBL] [Abstract][Full Text] [Related]
17. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of trandolapril alone or in combination with a calcium channel blocker in hypertensive patients over 60 years of age].
Gosse P; Vaur L; Dutrey-Dupagne C; Genes N; Destrée D; Elkik F
Ann Cardiol Angeiol (Paris); 1995 Nov; 44(9):517-24. PubMed ID: 8745662
[TBL] [Abstract][Full Text] [Related]
19. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings.
Itskovitz HD
Clin Ther; 1994; 16(3):490-504. PubMed ID: 7923316
[TBL] [Abstract][Full Text] [Related]
20. Blood pressure levels, risk factors and antihypertensive treatments: lessons from the SHEAF study.
Mallion JM; Genès N; Vaur L; Clerson P; Vaïsse B; Bobrie G; Chatellier G
J Hum Hypertens; 2001 Dec; 15(12):841-8. PubMed ID: 11773986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
